Karyopharm Therapeutics Inc. (KPTI)

14.60
0.98 7.20
NASDAQ : Health Technology
Prev Close 13.62
Open 13.81
Day Low/High 13.78 / 14.57
52 Wk Low/High 7.48 / 18.00
Volume 381.75K
Avg Volume 435.40K
Exchange NASDAQ
Shares Outstanding 49.53M
Market Cap 695.94M
EPS -2.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Karyopharm To Report Fourth Quarter And Year End 2017 Financial Results On March 15, 2018

Karyopharm To Report Fourth Quarter And Year End 2017 Financial Results On March 15, 2018

Conference Call Scheduled for Thursday, March 15, 2018 at 8:30 a.m. ET

Commit To Purchase Karyopharm Therapeutics At $12.50, Earn 30.6% Annualized Using Options

Commit To Purchase Karyopharm Therapeutics At $12.50, Earn 30.6% Annualized Using Options

Investors considering a purchase of Karyopharm Therapeutics Inc stock, but cautious about paying the going market price of $14.80/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the August put at the $12.50 strike, which has a bid at the time of this writing of $1.80.

Noteworthy Friday Option Activity: KPTI, SAM, SIGM

Noteworthy Friday Option Activity: KPTI, SAM, SIGM

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Karyopharm Therapeutics Inc , where a total of 802 contracts have traded so far, representing approximately 80,200 underlying shares. That amounts to about 69.4% of KPTI's average daily trading volume over the past month of 115,550 shares.

Commit To Buy Karyopharm Therapeutics At $10, Earn 35.2% Annualized Using Options

Commit To Buy Karyopharm Therapeutics At $10, Earn 35.2% Annualized Using Options

Investors eyeing a purchase of Karyopharm Therapeutics Inc shares, but cautious about paying the going market price of $11.35/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the May 2018 put at the $10 strike, which has a bid at the time of this writing of $1.65.

Karyopharm Therapeutics Stock Sees Short Interest Increase 16.4%

Karyopharm Therapeutics Stock Sees Short Interest Increase 16.4%

The most recent short interest data has been released for the 10/31/2017 settlement date, which shows a 335,533 share increase in total short interest for Karyopharm Therapeutics Inc , to 2,387,184, an increase of 16.35% since 10/13/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Karyopharm To Present Phase 1b/2 STOMP Clinical Data At The American Society Of Hematology 2017 Annual Meeting

Karyopharm To Present Phase 1b/2 STOMP Clinical Data At The American Society Of Hematology 2017 Annual Meeting

- Fourteen Abstracts Selected, Including Three Oral Presentations -

Karyopharm To Report Third Quarter 2017 Financial Results On November 2, 2017

Karyopharm To Report Third Quarter 2017 Financial Results On November 2, 2017

Conference Call Scheduled for Thursday, November 2, 2017 at 8:30 a.m. ET

Karyopharm Therapeutics Stock Sees Short Interest Decline 17%

Karyopharm Therapeutics Stock Sees Short Interest Decline 17%

The most recent short interest data has been released for the 09/15/2017 settlement date, which shows a 424,282 share decrease in total short interest for Karyopharm Therapeutics Inc , to 2,081,351, a decrease of 16.93% since 08/31/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Alnylam Shares Skyrocket on Clinical Study Results - Biotech Movers

Alnylam Shares Skyrocket on Clinical Study Results - Biotech Movers

Alnylam and Sanofi Genzyme announced positive topline results from a Phase 3 study of patisiran, which is being developed for patients with hereditary ATTR amyloidosis with polyneuropathy.

TheStreet Quant Rating: D (Sell)